Literature DB >> 24548268

Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin.

Manoela Tiago1, Edson Mendes de Oliveira, Carla Abdo Brohem, Paula Comune Pennacchi, Rafael Duarte Paes, Raquel Brandão Haga, Ana Campa, Silvia Berlanga de Moraes Barros, Keiran S Smalley, Silvya Stuchi Maria-Engler.   

Abstract

Melanoma is the most aggressive form of skin cancer and until recently, it was extremely resistant to radio-, immuno-, and chemotherapy. Despite the latest success of BRAF V600E-targeted therapies, responses are typically short lived and relapse is all but certain. Furthermore, a percentage (40%) of melanoma cells is BRAF wild type. Emerging evidence suggests a role for normal host cells in the occurrence of drug resistance. In the current study, we compared a variety of cell culture models with an organotypic incomplete skin culture model (the "dermal equivalent") to investigate the role of the tissue microenvironment in the response of melanoma cells to the chemotherapeutic agent doxorubicin (Dox). In the dermal equivalent model, consisting of fibroblasts embedded in type I collagen matrix, melanoma cells showed a decreased cytotoxic response when compared with less complex culture conditions, such as seeding on plastic cell culture plate (as monolayers cultures) or on collagen gel. We further investigated the role of the microenvironment in p53 induction and caspase 3 and 9 cleavage. Melanoma cell lines cultured on dermal equivalent showed decreased expression of p53 after Dox treatment, and this outcome was accompanied by induction of interleukin IL-6, IL-8, and matrix metalloproteinases 2 and 9. Here, we show that the growth of melanoma cells in the dermal equivalent model inflects drug responses by recapitulating important pro-survival features of the tumor microenvironment. These studies indicate that the presence of stroma enhances the drug resistance of melanoma in vitro, more closely mirroring the in vivo phenotype. Our data, thus, demonstrate the utility of organotypic cell culture models in providing essential context-dependent information critical for the development of new therapeutic strategies for melanoma. We believe that the organotypic model represents an improved screening platform to investigate novel anti-cancer agents, as it provides important insights into tumor-stromal interactions, thus assisting in the elucidation of chemoresistance mechanisms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24548268      PMCID: PMC4161062          DOI: 10.1089/ten.TEA.2013.0473

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  46 in total

1.  Vemurafenib sensitivity skin reaction after ipilimumab.

Authors:  James J Harding; Melissa Pulitzer; Paul B Chapman
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

Review 2.  Role of matrix metalloproteinases in melanoma cell invasion.

Authors:  Uta B Hofmann; Roland Houben; Eva-B Bröcker; Jürgen C Becker
Journal:  Biochimie       Date:  2005 Mar-Apr       Impact factor: 4.079

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Differential responses of proliferating versus quiescent cells to adriamycin.

Authors:  W Y Siu; T Arooz; R Y Poon
Journal:  Exp Cell Res       Date:  1999-07-10       Impact factor: 3.905

Review 5.  Tumor-stroma interactions: their role in the control of tumor cell invasion.

Authors:  P Zigrino; S Löffek; C Mauch
Journal:  Biochimie       Date:  2005 Mar-Apr       Impact factor: 4.079

6.  Second lung adenocarcinoma after combination chemotherapy in two patients with primary non-Hodgkin's lymphoma.

Authors:  T Yamada; K Shinohara; K Takeda; N Kameda; K Katsuki; K Ariyoshi; T Kamei
Journal:  Jpn J Clin Oncol       Date:  1999-04       Impact factor: 3.019

7.  Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity.

Authors:  Charles F Albright; Nilsa Graciani; Wei Han; Eddy Yue; Ross Stein; Zhihong Lai; Melody Diamond; Randine Dowling; Lisa Grimminger; Shu-Yun Zhang; Davette Behrens; Amy Musselman; Robert Bruckner; Mingzhu Zhang; Xiang Jiang; Daniel Hu; Anne Higley; Susan Dimeo; Maria Rafalski; Sandya Mandlekar; Bruce Car; Swamy Yeleswaram; Andrew Stern; Robert A Copeland; Andrew Combs; Steve P Seitz; George L Trainor; Rebecca Taub; Pearl Huang; Allen Oliff
Journal:  Mol Cancer Ther       Date:  2005-05       Impact factor: 6.261

Review 8.  Friends or foes - bipolar effects of the tumour stroma in cancer.

Authors:  Margareta M Mueller; Norbert E Fusenig
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

9.  Selective modulation of collagenase 1 gene expression by the chemotherapeutic agent doxorubicin.

Authors:  U Benbow; R Maitra; J W Hamilton; C E Brinckerhoff
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

10.  Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium.

Authors:  A F Olumi; G D Grossfeld; S W Hayward; P R Carroll; T D Tlsty; G R Cunha
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

View more
  15 in total

1.  Taxotere-induced elevated expression of IL8 in carcinoma-associated fibroblasts of breast invasive ductal cancer.

Authors:  Yingliang Li; Guohua Rong; Hua Kang
Journal:  Oncol Lett       Date:  2017-01-18       Impact factor: 2.967

Review 2.  The implication and potential applications of high-mobility group box 1 protein in breast cancer.

Authors:  Moonindranath Sohun; Huiling Shen
Journal:  Ann Transl Med       Date:  2016-06

3.  TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors.

Authors:  Érica Aparecida de Oliveira; Jagat Chauhan; Julia Rezende da Silva; Larissa Anastacio da Costa Carvalho; Diogo Dias; Danielle Gonçalves de Carvalho; Luis Roberto Masao Watanabe; Vito W Rebecca; Gordon Mills; Yiling Lu; Aloisio Souza Felipe da Silva; Márcia Edilaine Lopes Consolaro; Meenhard Herlyn; Patricia A Possik; Colin R Goding; Silvya Stuchi Maria-Engler
Journal:  Pharmacol Res       Date:  2021-09-22       Impact factor: 7.658

Review 4.  Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma.

Authors:  Linli Zhou; Kun Yang; Thomas Andl; R Randall Wickett; Yuhang Zhang
Journal:  J Cancer       Date:  2015-06-23       Impact factor: 4.207

5.  Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells.

Authors:  Kamolporn Amornsupak; Tonkla Insawang; Peti Thuwajit; Pornchai O-Charoenrat; Suzanne A Eccles; Chanitra Thuwajit
Journal:  BMC Cancer       Date:  2014-12-15       Impact factor: 4.430

6.  Use of a Tissue Engineered Human Skin Model to Investigate the Effects of Wounding and of an Anti-Inflammatory on Melanoma Cell Invasion.

Authors:  Claudia Mirian de Godoy Marques; Sheila MacNeil
Journal:  PLoS One       Date:  2016-06-07       Impact factor: 3.240

7.  Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells.

Authors:  Svetlana Skolekova; Miroslava Matuskova; Martin Bohac; Lenka Toro; Erika Durinikova; Silvia Tyciakova; Lucia Demkova; Jan Gursky; Lucia Kucerova
Journal:  Cell Commun Signal       Date:  2016-01-12       Impact factor: 5.712

8.  Fibroblast-associated tumour microenvironment induces vascular structure-networked tumouroid.

Authors:  Sang Woo Lee; Hyeong Seob Kwak; Myoung-Hee Kang; Yun-Yong Park; Gi Seok Jeong
Journal:  Sci Rep       Date:  2018-02-05       Impact factor: 4.379

9.  CADM1 is a TWIST1-regulated suppressor of invasion and survival.

Authors:  Edward J Hartsough; Michele B Weiss; Shea A Heilman; Timothy J Purwin; Curtis H Kugel; Sheera R Rosenbaum; Dan A Erkes; Manoela Tiago; Kim HooKim; Inna Chervoneva; Andrew E Aplin
Journal:  Cell Death Dis       Date:  2019-03-25       Impact factor: 8.469

10.  Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.

Authors:  Dan A Erkes; Weijia Cai; Ileine M Sanchez; Timothy J Purwin; Corey Rogers; Conroy O Field; Adam C Berger; Edward J Hartsough; Ulrich Rodeck; Emad S Alnemri; Andrew E Aplin
Journal:  Cancer Discov       Date:  2019-12-03       Impact factor: 38.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.